Boost­ing check­point in­hibitor ef­fi­ca­cy via the mi­cro­bio­me

5 years ago

How the sur­gi­cal set­ting con­tributes to the opi­oid cri­sis

5 years ago

Fol­licum, a Swedish biotech com­pa­ny born to find a treat­ment for hair loss, now has di­a­betes in its crosshairs

5 years ago

Ap­ta­hem – a Swedish biotech aim­ing to win the race against sep­sis

5 years ago

Fo­cus on tar­get­ed val­ue cre­ation and in­creased strate­gic man­age­ment is key to ad­dress chal­lenges with R&D bio­phar­ma­ceu­ti­cal pre­c­om­pet­i­tive col­lab­o­ra­tions

5 years ago

Io­n­is is fo­cused on treat­ing the un­treat­able with med­ical break­throughs for pa­tients

5 years ago

Cereno Sci­en­tif­ic is dri­ving a new par­a­digm of throm­bo­sis pre­ven­tion with­out as­so­ci­at­ed bleed­ing-risks

5 years ago

Nov­el he­pati­tis B virus nu­cle­o­cap­sid for­ma­tion in­hibitor CB-HBV-001 demon­strates ex­cel­lent an­ti-HBV ac­tiv­i­ty

5 years ago

How tri­al in­no­va­tion in Aus­tralia is get­ting ther­a­pies to pa­tients soon­er

5 years ago

With ac­cess to 1.4 bil­lion po­ten­tial Asia-Pa­cif­ic tri­al par­tic­i­pants, Novotech CRO can help get your drug to mar­ket faster

5 years ago

PPD Biotech pan­el: Five biotech lead­ers of­fer their sur­pris­ing takes on the big trends shap­ing the in­dus­try in the Bay Area and be­yond

5 years ago

A Swedish biotech is tar­get­ing throm­bo­sis us­ing the body's own de­fense sys­tem to pre­vent blood clots with low­er risk of bleed­ing as­so­ci­at­ed with cur­rent an­tithrom­bot­ic ther­a­pies

5 years ago

The first FDA-ap­proved dig­i­tal pill — what it means for phar­ma

5 years ago

Is the phar­ma busi­ness mod­el ready for pre­ci­sion med­i­cine?

5 years ago

PPD Biotech pan­el: Five lead­ers in the Boston hub eval­u­ate the top trends — and where we’re all head­ed in the next 5 years

5 years ago

Bio­phar­ma­ceu­ti­cal Deal­mak­ers’ In­ten­tions in 2018: Sup­ply and De­mand Ex­pec­ta­tions and Im­bal­ances

5 years ago

Swedish Biotech Dex­Tech Med­ical shoots for bil­lion dol­lar prostate can­cer mar­ket — con­cludes phI­Ib study ear­ly

5 years ago

Bio­phar­ma­ceu­ti­cal Deal­mak­ers’ In­ten­tions in 2018: Bull­ish Run to Con­tin­ue Amidst Signs of Greater Risk Aver­sion

5 years ago

Min­i­mal Resid­ual Dis­ease: A Prog­nos­tic Fac­tor Mov­ing the Nee­dle in Pa­tient Care

5 years ago

For­get about greed, Pres­i­dent Trump: the vil­lain re­spon­si­ble for high drug prices is in­ef­fi­cien­cy

6 years ago

The Evolv­ing Over­all Sur­vival Ex­pec­ta­tions of Pa­tients with Re­lapsed or Re­frac­to­ry Mul­ti­ple Myelo­ma

6 years ago

The win­ners and losers of the Swedish biotech in­dus­try IPO fren­zy

6 years ago

How as­set sup­ply and de­mand is shap­ing bio­phar­ma­ceu­ti­cal deal­mak­ing

6 years ago

Bio­phar­ma­ceu­ti­cal Deal­mak­ers’ In­ten­tions in 2017: In­flu­ences and Hot Spots

6 years ago
First page Previous page 45678 Next page Last page
A service from the Financial Times